Marchio Albert N II 4
4 · Fresh Tracks Therapeutics, Inc. · Filed Jan 9, 2024
Insider Transaction Report
Form 4
MARCHIO ALBERT N II
Chief Financial Officer
Transactions
- Disposition to Issuer
Restricted Stock Units
2023-12-28$0.91/sh−1,250$1,138→ 0 total→ Common Stock (1,250 underlying)
Footnotes (2)
- [F1]Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment").
- [F2]The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs.